FCM
EVFM

Farallon Capital Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Farallon Capital Management’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,394
Closed -$1.01M – 79
2015
Q3 		$1.01M Buy
1,394
+5
+0.4% +$5.37K 0.01% 81
2015
Q2 		$1.13M Hold
1,389
– – 0.02% 92
2015
Q1 		$1.03M Hold
1,389
– – 0.02% 90
2014
Q4 		$935K Buy
+1,389
New +$1.05M 0.01% 84

Other funds holding EVFM

CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Farallon Capital Management's EVFM Position: Q4 2015 in Review

Farallon Capital Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2015, closing a stake of 1,394 shares — an estimated $1.01M sold.

Farallon Capital Management first reported a position in EVFM in Q4 2014 and held it in 4 quarters. The position peaked at $1.13M in Q2 2015. 24 funds tracked by Wall St. Rank hold EVFM as of Q4 2015.

  • Farallon Capital Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Farallon Capital Management sold 1,394 Evofem Biosciences, Inc. Common Stock shares in Q4 2015, an estimated $1.01M.
  • Farallon Capital Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2014 and held it in 4 quarters.
  • Farallon Capital Management's Evofem Biosciences, Inc. Common Stock position peaked at $1.13M in Q2 2015.
  • 24 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2015.

Based on Farallon Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.